Loading…
Anti‐TNF alpha medications and neuropathy
We studied the clinical, electrophysiological, and pathological features, outcome, and frequency of anti‐tumor necrosis factor alpha (a‐TNF) medications‐induced neuropathies (ATIN) in patients with inflammatory disorders. Of 2,017 patients treated with a‐TNF medication, 12 patients met our inclusion...
Saved in:
| Published in: | Journal of the peripheral nervous system 2015-12, Vol.20 (4), p.397-402 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4127-ecf40387d67d83c6c4efde2917ec4f88468308b3b274fec13b58084da770f6f53 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4127-ecf40387d67d83c6c4efde2917ec4f88468308b3b274fec13b58084da770f6f53 |
| container_end_page | 402 |
| container_issue | 4 |
| container_start_page | 397 |
| container_title | Journal of the peripheral nervous system |
| container_volume | 20 |
| creator | Tsouni, Pinelopi Bill, Olivier Truffert, André Liaudat, Christelle Ochsner, François Steck, Andreas J. Kuntzer, Thierry |
| description | We studied the clinical, electrophysiological, and pathological features, outcome, and frequency of anti‐tumor necrosis factor alpha (a‐TNF) medications‐induced neuropathies (ATIN) in patients with inflammatory disorders. Of 2,017 patients treated with a‐TNF medication, 12 patients met our inclusion criteria for a prevalence of 0.60% and an incidence of 0.4 cases per 1,000 person‐years. The median time from a‐TNF medication treatment to ATIN was 16.8 months (range 2–60 months). Six patients had focal or multifocal peripheral neuropathies. The other six had generalized neuropathies. For all, a‐TNF medication was stopped. Seven patients received immunoglobulin infusions. ATIN outcome was favorable in all but one patient. ATINs are rare and heterogeneous neuropathies. In 10 patients, the neuropathy was “inflammatory”, suggesting that it could be due to systemic pro‐inflammatory effects of a‐TNF agents. |
| doi_str_mv | 10.1111/jns.12147 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1780514641</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3923509181</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4127-ecf40387d67d83c6c4efde2917ec4f88468308b3b274fec13b58084da770f6f53</originalsourceid><addsrcrecordid>eNqN0E1LwzAYB_AgipvTg19ACl4U6Za3NulxDOcLYx6c55CmCevo2pq0SG9-BD-jn8RopwdB8MnhyeHHH54_AKcIjpGfyaZ0Y4QRZXtgiCKchBxitu__kEdhQnkyAEfObSBELEHJIRjgmMAEEzIEV9Oyyd9f31bLeSCLei2Drc5yJZu8Kl0gyywodWurWjbr7hgcGFk4fbLbI_A0v17NbsPFw83dbLoIFUWYhVoZCglnWcwyTlSsqDaZxgliWlHDOY05gTwlKWbUaIVIGnHIaSYZgyY2ERmBiz63ttVzq10jtrlTuihkqavWCcQ4jBCNKfoHjf2hzEtPz3_RTdXa0h_iVcR8bf55ddkrZSvnrDaitvlW2k4gKD7LFr5s8VW2t2e7xDb1rf3I73Y9mPTgJS9093eSuF8-9pEfnbWGcw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1757529292</pqid></control><display><type>article</type><title>Anti‐TNF alpha medications and neuropathy</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Tsouni, Pinelopi ; Bill, Olivier ; Truffert, André ; Liaudat, Christelle ; Ochsner, François ; Steck, Andreas J. ; Kuntzer, Thierry</creator><creatorcontrib>Tsouni, Pinelopi ; Bill, Olivier ; Truffert, André ; Liaudat, Christelle ; Ochsner, François ; Steck, Andreas J. ; Kuntzer, Thierry</creatorcontrib><description>We studied the clinical, electrophysiological, and pathological features, outcome, and frequency of anti‐tumor necrosis factor alpha (a‐TNF) medications‐induced neuropathies (ATIN) in patients with inflammatory disorders. Of 2,017 patients treated with a‐TNF medication, 12 patients met our inclusion criteria for a prevalence of 0.60% and an incidence of 0.4 cases per 1,000 person‐years. The median time from a‐TNF medication treatment to ATIN was 16.8 months (range 2–60 months). Six patients had focal or multifocal peripheral neuropathies. The other six had generalized neuropathies. For all, a‐TNF medication was stopped. Seven patients received immunoglobulin infusions. ATIN outcome was favorable in all but one patient. ATINs are rare and heterogeneous neuropathies. In 10 patients, the neuropathy was “inflammatory”, suggesting that it could be due to systemic pro‐inflammatory effects of a‐TNF agents.</description><identifier>ISSN: 1085-9489</identifier><identifier>EISSN: 1529-8027</identifier><identifier>DOI: 10.1111/jns.12147</identifier><identifier>PMID: 26309233</identifier><language>eng</language><publisher>Malden, USA: Wiley Periodicals, Inc</publisher><subject>Adalimumab - adverse effects ; Adalimumab - therapeutic use ; Adult ; Aged ; anti‐TNF alpha ; Autoimmune Diseases - drug therapy ; demyelination ; Electrodiagnosis ; Etanercept - adverse effects ; Etanercept - therapeutic use ; Female ; Humans ; inflammation ; Infliximab - adverse effects ; Infliximab - therapeutic use ; Male ; Middle Aged ; Neural Conduction - physiology ; neuropathies ; Peripheral Nervous System Diseases - chemically induced ; Peripheral Nervous System Diseases - diagnosis ; Peripheral Nervous System Diseases - physiopathology ; Rheumatic Diseases - drug therapy ; Tumor Necrosis Factor-alpha - antagonists & inhibitors ; Tumor necrosis factor-TNF</subject><ispartof>Journal of the peripheral nervous system, 2015-12, Vol.20 (4), p.397-402</ispartof><rights>2015 Peripheral Nerve Society</rights><rights>2015 Peripheral Nerve Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4127-ecf40387d67d83c6c4efde2917ec4f88468308b3b274fec13b58084da770f6f53</citedby><cites>FETCH-LOGICAL-c4127-ecf40387d67d83c6c4efde2917ec4f88468308b3b274fec13b58084da770f6f53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26309233$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tsouni, Pinelopi</creatorcontrib><creatorcontrib>Bill, Olivier</creatorcontrib><creatorcontrib>Truffert, André</creatorcontrib><creatorcontrib>Liaudat, Christelle</creatorcontrib><creatorcontrib>Ochsner, François</creatorcontrib><creatorcontrib>Steck, Andreas J.</creatorcontrib><creatorcontrib>Kuntzer, Thierry</creatorcontrib><title>Anti‐TNF alpha medications and neuropathy</title><title>Journal of the peripheral nervous system</title><addtitle>J Peripher Nerv Syst</addtitle><description>We studied the clinical, electrophysiological, and pathological features, outcome, and frequency of anti‐tumor necrosis factor alpha (a‐TNF) medications‐induced neuropathies (ATIN) in patients with inflammatory disorders. Of 2,017 patients treated with a‐TNF medication, 12 patients met our inclusion criteria for a prevalence of 0.60% and an incidence of 0.4 cases per 1,000 person‐years. The median time from a‐TNF medication treatment to ATIN was 16.8 months (range 2–60 months). Six patients had focal or multifocal peripheral neuropathies. The other six had generalized neuropathies. For all, a‐TNF medication was stopped. Seven patients received immunoglobulin infusions. ATIN outcome was favorable in all but one patient. ATINs are rare and heterogeneous neuropathies. In 10 patients, the neuropathy was “inflammatory”, suggesting that it could be due to systemic pro‐inflammatory effects of a‐TNF agents.</description><subject>Adalimumab - adverse effects</subject><subject>Adalimumab - therapeutic use</subject><subject>Adult</subject><subject>Aged</subject><subject>anti‐TNF alpha</subject><subject>Autoimmune Diseases - drug therapy</subject><subject>demyelination</subject><subject>Electrodiagnosis</subject><subject>Etanercept - adverse effects</subject><subject>Etanercept - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>inflammation</subject><subject>Infliximab - adverse effects</subject><subject>Infliximab - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neural Conduction - physiology</subject><subject>neuropathies</subject><subject>Peripheral Nervous System Diseases - chemically induced</subject><subject>Peripheral Nervous System Diseases - diagnosis</subject><subject>Peripheral Nervous System Diseases - physiopathology</subject><subject>Rheumatic Diseases - drug therapy</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><subject>Tumor necrosis factor-TNF</subject><issn>1085-9489</issn><issn>1529-8027</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNqN0E1LwzAYB_AgipvTg19ACl4U6Za3NulxDOcLYx6c55CmCevo2pq0SG9-BD-jn8RopwdB8MnhyeHHH54_AKcIjpGfyaZ0Y4QRZXtgiCKchBxitu__kEdhQnkyAEfObSBELEHJIRjgmMAEEzIEV9Oyyd9f31bLeSCLei2Drc5yJZu8Kl0gyywodWurWjbr7hgcGFk4fbLbI_A0v17NbsPFw83dbLoIFUWYhVoZCglnWcwyTlSsqDaZxgliWlHDOY05gTwlKWbUaIVIGnHIaSYZgyY2ERmBiz63ttVzq10jtrlTuihkqavWCcQ4jBCNKfoHjf2hzEtPz3_RTdXa0h_iVcR8bf55ddkrZSvnrDaitvlW2k4gKD7LFr5s8VW2t2e7xDb1rf3I73Y9mPTgJS9093eSuF8-9pEfnbWGcw</recordid><startdate>201512</startdate><enddate>201512</enddate><creator>Tsouni, Pinelopi</creator><creator>Bill, Olivier</creator><creator>Truffert, André</creator><creator>Liaudat, Christelle</creator><creator>Ochsner, François</creator><creator>Steck, Andreas J.</creator><creator>Kuntzer, Thierry</creator><general>Wiley Periodicals, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201512</creationdate><title>Anti‐TNF alpha medications and neuropathy</title><author>Tsouni, Pinelopi ; Bill, Olivier ; Truffert, André ; Liaudat, Christelle ; Ochsner, François ; Steck, Andreas J. ; Kuntzer, Thierry</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4127-ecf40387d67d83c6c4efde2917ec4f88468308b3b274fec13b58084da770f6f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adalimumab - adverse effects</topic><topic>Adalimumab - therapeutic use</topic><topic>Adult</topic><topic>Aged</topic><topic>anti‐TNF alpha</topic><topic>Autoimmune Diseases - drug therapy</topic><topic>demyelination</topic><topic>Electrodiagnosis</topic><topic>Etanercept - adverse effects</topic><topic>Etanercept - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>inflammation</topic><topic>Infliximab - adverse effects</topic><topic>Infliximab - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neural Conduction - physiology</topic><topic>neuropathies</topic><topic>Peripheral Nervous System Diseases - chemically induced</topic><topic>Peripheral Nervous System Diseases - diagnosis</topic><topic>Peripheral Nervous System Diseases - physiopathology</topic><topic>Rheumatic Diseases - drug therapy</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><topic>Tumor necrosis factor-TNF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tsouni, Pinelopi</creatorcontrib><creatorcontrib>Bill, Olivier</creatorcontrib><creatorcontrib>Truffert, André</creatorcontrib><creatorcontrib>Liaudat, Christelle</creatorcontrib><creatorcontrib>Ochsner, François</creatorcontrib><creatorcontrib>Steck, Andreas J.</creatorcontrib><creatorcontrib>Kuntzer, Thierry</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the peripheral nervous system</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tsouni, Pinelopi</au><au>Bill, Olivier</au><au>Truffert, André</au><au>Liaudat, Christelle</au><au>Ochsner, François</au><au>Steck, Andreas J.</au><au>Kuntzer, Thierry</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti‐TNF alpha medications and neuropathy</atitle><jtitle>Journal of the peripheral nervous system</jtitle><addtitle>J Peripher Nerv Syst</addtitle><date>2015-12</date><risdate>2015</risdate><volume>20</volume><issue>4</issue><spage>397</spage><epage>402</epage><pages>397-402</pages><issn>1085-9489</issn><eissn>1529-8027</eissn><abstract>We studied the clinical, electrophysiological, and pathological features, outcome, and frequency of anti‐tumor necrosis factor alpha (a‐TNF) medications‐induced neuropathies (ATIN) in patients with inflammatory disorders. Of 2,017 patients treated with a‐TNF medication, 12 patients met our inclusion criteria for a prevalence of 0.60% and an incidence of 0.4 cases per 1,000 person‐years. The median time from a‐TNF medication treatment to ATIN was 16.8 months (range 2–60 months). Six patients had focal or multifocal peripheral neuropathies. The other six had generalized neuropathies. For all, a‐TNF medication was stopped. Seven patients received immunoglobulin infusions. ATIN outcome was favorable in all but one patient. ATINs are rare and heterogeneous neuropathies. In 10 patients, the neuropathy was “inflammatory”, suggesting that it could be due to systemic pro‐inflammatory effects of a‐TNF agents.</abstract><cop>Malden, USA</cop><pub>Wiley Periodicals, Inc</pub><pmid>26309233</pmid><doi>10.1111/jns.12147</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1085-9489 |
| ispartof | Journal of the peripheral nervous system, 2015-12, Vol.20 (4), p.397-402 |
| issn | 1085-9489 1529-8027 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1780514641 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Adalimumab - adverse effects Adalimumab - therapeutic use Adult Aged anti‐TNF alpha Autoimmune Diseases - drug therapy demyelination Electrodiagnosis Etanercept - adverse effects Etanercept - therapeutic use Female Humans inflammation Infliximab - adverse effects Infliximab - therapeutic use Male Middle Aged Neural Conduction - physiology neuropathies Peripheral Nervous System Diseases - chemically induced Peripheral Nervous System Diseases - diagnosis Peripheral Nervous System Diseases - physiopathology Rheumatic Diseases - drug therapy Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor necrosis factor-TNF |
| title | Anti‐TNF alpha medications and neuropathy |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T23%3A33%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti%E2%80%90TNF%20alpha%20medications%20and%20neuropathy&rft.jtitle=Journal%20of%20the%20peripheral%20nervous%20system&rft.au=Tsouni,%20Pinelopi&rft.date=2015-12&rft.volume=20&rft.issue=4&rft.spage=397&rft.epage=402&rft.pages=397-402&rft.issn=1085-9489&rft.eissn=1529-8027&rft_id=info:doi/10.1111/jns.12147&rft_dat=%3Cproquest_cross%3E3923509181%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4127-ecf40387d67d83c6c4efde2917ec4f88468308b3b274fec13b58084da770f6f53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1757529292&rft_id=info:pmid/26309233&rfr_iscdi=true |